184 related articles for article (PubMed ID: 34678899)
1. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
2. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
3. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
4. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
5. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
6. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
8. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
9. Breaking the chains of lipoprotein lipase deficiency: A pediatric perspective on the efficacy and safety of Volanesorsen.
den Hollander B; Brands MM; Nijhuis IJM; Doude van Troostwijk LJAE; van Essen P; Hofsteenge GH; Koot BG; Müller AR; Tseng LA; Stroes ESG; van de Ven PM; Wiegman A; van Karnebeek CDM
Mol Genet Metab; 2024 May; 142(1):108347. PubMed ID: 38401382
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
11. Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene.
Kim KY; Heo YJ; Ko JM; Lee YA; Shin CH; Ki CS; Lee YJ
BMC Endocr Disord; 2024 Apr; 24(1):47. PubMed ID: 38622573
[TBL] [Abstract][Full Text] [Related]
12. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
13. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
15. Etiology and emerging treatments for familial chylomicronemia syndrome.
Spagnuolo CM; Hegele RA
Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
[TBL] [Abstract][Full Text] [Related]
16. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare APOA5 mutation: a case report.
Makhmudova U; Schulze PC; Lorkowski S; März W; Geiling JA; Weingärtner O
J Med Case Rep; 2024 Jun; 18(1):278. PubMed ID: 38872171
[TBL] [Abstract][Full Text] [Related]
17. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
18. Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.
Blom DJ; O'Dea L; Digenio A; Alexander VJ; Karwatowska-Prokopczuk E; Williams KR; Hemphill L; Muñiz-Grijalvo O; Santos RD; Baum S; Witztum JL
J Clin Lipidol; 2018; 12(5):1234-1243.e5. PubMed ID: 30318066
[TBL] [Abstract][Full Text] [Related]
19. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
20. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]